Aeglea Bio Therapeutics Inc (AGLE) Given Consensus Rating of “Buy” by Analysts

Share on StockTwits

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has received an average recommendation of “Buy” from the six brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $26.00.

Several brokerages have commented on AGLE. Wells Fargo & Co cut shares of Aeglea Bio Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, September 4th. Zacks Investment Research cut shares of Aeglea Bio Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 14th. Finally, BMO Capital Markets assumed coverage on shares of Aeglea Bio Therapeutics in a report on Thursday, June 14th. They set an “outperform” rating and a $21.00 price target for the company.

Shares of AGLE traded up $0.05 during midday trading on Friday, hitting $9.79. The stock had a trading volume of 274,879 shares, compared to its average volume of 205,588. Aeglea Bio Therapeutics has a fifty-two week low of $3.75 and a fifty-two week high of $12.00. The stock has a market cap of $211.32 million, a price-to-earnings ratio of -5.44 and a beta of 0.16.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last announced its earnings results on Thursday, August 9th. The biotechnology company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.10). Aeglea Bio Therapeutics had a negative return on equity of 57.15% and a negative net margin of 480.92%. The firm had revenue of $2.38 million during the quarter. On average, sell-side analysts forecast that Aeglea Bio Therapeutics will post -1.8 EPS for the current year.

In related news, insider Aaron Schuchart sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 27th. The shares were sold at an average price of $9.50, for a total transaction of $57,000.00. Following the completion of the sale, the insider now directly owns 8,400 shares in the company, valued at $79,800. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 18.30% of the company’s stock.

Several hedge funds have recently bought and sold shares of the stock. Spark Investment Management LLC boosted its holdings in shares of Aeglea Bio Therapeutics by 69.6% during the first quarter. Spark Investment Management LLC now owns 19,000 shares of the biotechnology company’s stock worth $188,000 after purchasing an additional 7,800 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Aeglea Bio Therapeutics during the second quarter worth approximately $131,000. Rhumbline Advisers acquired a new stake in shares of Aeglea Bio Therapeutics during the second quarter worth approximately $161,000. Blair William & Co. IL boosted its holdings in shares of Aeglea Bio Therapeutics by 142.8% during the first quarter. Blair William & Co. IL now owns 27,204 shares of the biotechnology company’s stock worth $270,000 after purchasing an additional 16,000 shares during the period. Finally, A.R.T. Advisors LLC acquired a new stake in shares of Aeglea Bio Therapeutics during the first quarter worth approximately $183,000. Institutional investors and hedge funds own 66.50% of the company’s stock.

Aeglea Bio Therapeutics Company Profile

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

Featured Article: Asset Allocation

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.